AP958A - Arylsulfonyl hydroxamic acid derivatives. - Google Patents

Arylsulfonyl hydroxamic acid derivatives. Download PDF

Info

Publication number: AP958A
Authority: AP; ARIPO
Prior art keywords: aryl; alkyl; heteroaryl; hydrogen; alkoxy
Prior art date: 1997-02-11

Application number

APAP/P/1998/001179A

Other languages

English (en)

Inventor

Kim Francis Mcclure

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-02-11

Filing date

1998-02-05

Publication date

2001-04-17

1998-02-05 Application filed by Pfizer filed Critical Pfizer

2001-04-17 Application granted granted Critical

2001-04-17 Publication of AP958A publication Critical patent/AP958A/en

Links

-1 Arylsulfonyl hydroxamic Chemical compound 0.000 title claims abstract description 80
239000002253 acid Substances 0.000 title description 12
150000001875 compounds Chemical class 0.000 claims abstract description 97
238000011282 treatment Methods 0.000 claims abstract description 22
201000010099 disease Diseases 0.000 claims abstract description 16
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 16
238000004519 manufacturing process Methods 0.000 claims abstract description 16
102000002274 Matrix Metalloproteinases Human genes 0.000 claims abstract description 15
108010000684 Matrix Metalloproteinases Proteins 0.000 claims abstract description 15
230000000694 effects Effects 0.000 claims abstract description 11
206010028980 Neoplasm Diseases 0.000 claims abstract description 9
206010003246 arthritis Diseases 0.000 claims abstract description 8
201000011510 cancer Diseases 0.000 claims abstract description 8
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims abstract description 8
206010040047 Sepsis Diseases 0.000 claims abstract description 7
206010040070 Septic Shock Diseases 0.000 claims abstract description 7
208000028169 periodontal disease Diseases 0.000 claims abstract description 7
230000036303 septic shock Effects 0.000 claims abstract description 7
208000030507 AIDS Diseases 0.000 claims abstract description 6
206010014989 Epidermolysis bullosa Diseases 0.000 claims abstract description 6
229940035676 analgesics Drugs 0.000 claims abstract description 6
239000000730 antalgic agent Substances 0.000 claims abstract description 6
231100000433 cytotoxic Toxicity 0.000 claims abstract description 6
230000001472 cytotoxic effect Effects 0.000 claims abstract description 6
208000037803 restenosis Diseases 0.000 claims abstract description 6
208000002780 macular degeneration Diseases 0.000 claims abstract description 5
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims abstract description 5
125000000217 alkyl group Chemical group 0.000 claims description 85
ZXKINMCYCKHYFR-UHFFFAOYSA-N aminooxidanide Chemical compound [O-]N ZXKINMCYCKHYFR-UHFFFAOYSA-N 0.000 claims description 81
239000001257 hydrogen Substances 0.000 claims description 69
229910052739 hydrogen Inorganic materials 0.000 claims description 69
125000001072 heteroaryl group Chemical group 0.000 claims description 57
125000003118 aryl group Chemical group 0.000 claims description 55
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 47
125000003545 alkoxy group Chemical group 0.000 claims description 37
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 28
102000003390 tumor necrosis factor Human genes 0.000 claims description 28
125000005842 heteroatom Chemical group 0.000 claims description 21
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 21
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 19
238000000034 method Methods 0.000 claims description 19
125000004104 aryloxy group Chemical group 0.000 claims description 18
229910052799 carbon Inorganic materials 0.000 claims description 18
230000005764 inhibitory process Effects 0.000 claims description 18
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 17
229910052757 nitrogen Inorganic materials 0.000 claims description 17
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 16
125000002757 morpholinyl group Chemical group 0.000 claims description 16
239000001301 oxygen Substances 0.000 claims description 16
229910052760 oxygen Inorganic materials 0.000 claims description 16
125000000719 pyrrolidinyl group Chemical group 0.000 claims description 16
150000003839 salts Chemical class 0.000 claims description 15
125000005110 aryl thio group Chemical group 0.000 claims description 13
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 13
241000124008 Mammalia Species 0.000 claims description 12
125000003386 piperidinyl group Chemical group 0.000 claims description 12
125000001424 substituent group Chemical group 0.000 claims description 12
125000002393 azetidinyl group Chemical group 0.000 claims description 11
125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 10
125000004568 thiomorpholinyl group Chemical group 0.000 claims description 10
125000005553 heteroaryloxy group Chemical group 0.000 claims description 9
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 9
125000005936 piperidyl group Chemical group 0.000 claims description 8
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
208000025865 Ulcer Diseases 0.000 claims description 7
125000001769 aryl amino group Chemical group 0.000 claims description 7
125000001153 fluoro group Chemical group F* 0.000 claims description 7
125000005241 heteroarylamino group Chemical group 0.000 claims description 7
150000002431 hydrogen Chemical class 0.000 claims description 7
230000036269 ulceration Effects 0.000 claims description 7
125000004414 alkyl thio group Chemical group 0.000 claims description 6
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 6
125000001309 chloro group Chemical group Cl* 0.000 claims description 6
229910014585 C2-Ce Inorganic materials 0.000 claims description 5
125000004423 acyloxy group Chemical group 0.000 claims description 5
125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims description 5
125000004193 piperazinyl group Chemical group 0.000 claims description 5
125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims description 5
150000008575 L-amino acids Chemical class 0.000 claims description 4
239000002246 antineoplastic agent Substances 0.000 claims description 4
125000005135 aryl sulfinyl group Chemical group 0.000 claims description 4
125000004391 aryl sulfonyl group Chemical group 0.000 claims description 4
125000005843 halogen group Chemical group 0.000 claims description 4
125000000623 heterocyclic group Chemical group 0.000 claims description 4
125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 4
125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims description 4
125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims description 4
125000005035 acylthio group Chemical group 0.000 claims description 3
125000003342 alkenyl group Chemical group 0.000 claims description 3
125000003282 alkyl amino group Chemical group 0.000 claims description 3
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
JMBOAEVTEXTTPO-BXUZGUMPSA-N (2r,4r)-1-[3-(4-fluorophenoxy)propylsulfonyl]-2-(hydroxycarbamoyl)piperidine-4-carboxylic acid Chemical compound ONC(=O)[C@H]1C[C@H](C(O)=O)CCN1S(=O)(=O)CCCOC1=CC=C(F)C=C1 JMBOAEVTEXTTPO-BXUZGUMPSA-N 0.000 claims description 2
125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 2
125000000753 cycloalkyl group Chemical group 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
125000000041 C6-C10 aryl group Chemical group 0.000 claims 41
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 13
125000004356 hydroxy functional group Chemical group O* 0.000 claims 10
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 8
125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 7
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 5
125000006719 (C6-C10) aryl (C1-C6) alkyl group Chemical group 0.000 claims 5
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 4
125000005368 heteroarylthio group Chemical group 0.000 claims 3
206010039705 Scleritis Diseases 0.000 claims 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
PDFDFBYWRAAPBF-RDTXWAMCSA-N (2r,4r)-1-[4-[(4-fluorophenyl)methoxy]phenyl]sulfonyl-2-(hydroxycarbamoyl)piperidine-4-carboxylic acid Chemical compound ONC(=O)[C@H]1C[C@H](C(O)=O)CCN1S(=O)(=O)C(C=C1)=CC=C1OCC1=CC=C(F)C=C1 PDFDFBYWRAAPBF-RDTXWAMCSA-N 0.000 claims 1
KEVSGIPPEHZMGV-OALZAMAHSA-N (2r,4r)-n-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-(piperazine-1-carbonyl)piperidine-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1S(=O)(=O)N1[C@@H](C(=O)NO)C[C@H](C(=O)N2CCNCC2)CC1 KEVSGIPPEHZMGV-OALZAMAHSA-N 0.000 claims 1
125000006720 (C1-C6) alkyl (C6-C10) aryl group Chemical group 0.000 claims 1
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
101100333779 Oryza sativa subsp. indica ERS1 gene Proteins 0.000 claims 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract description 4
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract description 2
229930012538 Paclitaxel Natural products 0.000 abstract description 2
229940009456 adriamycin Drugs 0.000 abstract description 2
229930013930 alkaloid Natural products 0.000 abstract description 2
238000002648 combination therapy Methods 0.000 abstract description 2
229940079593 drug Drugs 0.000 abstract description 2
239000003814 drug Substances 0.000 abstract description 2
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 abstract description 2
229960005420 etoposide Drugs 0.000 abstract description 2
229960001592 paclitaxel Drugs 0.000 abstract description 2
229910052697 platinum Inorganic materials 0.000 abstract description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract description 2
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract description 2
229940063683 taxotere Drugs 0.000 abstract description 2
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 abstract description 2
229960004528 vincristine Drugs 0.000 abstract description 2
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 abstract description 2
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 abstract 1
WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 abstract 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 abstract 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 71
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 69
239000000203 mixture Substances 0.000 description 64
229910052684 Cerium Inorganic materials 0.000 description 46
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 43
239000000243 solution Substances 0.000 description 43
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 40
238000006243 chemical reaction Methods 0.000 description 35
239000007787 solid Substances 0.000 description 33
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 32
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 25
125000006239 protecting group Chemical group 0.000 description 25
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 25
239000000706 filtrate Substances 0.000 description 21
150000004702 methyl esters Chemical class 0.000 description 19
239000003112 inhibitor Substances 0.000 description 17
238000002360 preparation method Methods 0.000 description 16
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
238000003556 assay Methods 0.000 description 15
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 14
239000012267 brine Substances 0.000 description 14
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
238000001914 filtration Methods 0.000 description 13
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 12
238000007792 addition Methods 0.000 description 12
239000000758 substrate Substances 0.000 description 12
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 12
239000012044 organic layer Substances 0.000 description 11
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 9
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 9
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
239000003921 oil Substances 0.000 description 9
235000019198 oils Nutrition 0.000 description 9
229910052938 sodium sulfate Inorganic materials 0.000 description 9
235000011152 sodium sulphate Nutrition 0.000 description 9
108060005980 Collagenase Proteins 0.000 description 8
102000029816 Collagenase Human genes 0.000 description 8
102000004190 Enzymes Human genes 0.000 description 8
108090000790 Enzymes Proteins 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 8
108090000631 Trypsin Proteins 0.000 description 8
102000004142 Trypsin Human genes 0.000 description 8
239000012131 assay buffer Substances 0.000 description 8
229960002424 collagenase Drugs 0.000 description 8
229940088598 enzyme Drugs 0.000 description 8
150000002148 esters Chemical class 0.000 description 8
238000003818 flash chromatography Methods 0.000 description 8
239000012588 trypsin Substances 0.000 description 8
102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 7
108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 7
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 7
239000007983 Tris buffer Substances 0.000 description 7
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 7
238000010992 reflux Methods 0.000 description 7
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
239000006260 foam Substances 0.000 description 6
239000012299 nitrogen atmosphere Substances 0.000 description 6
238000000746 purification Methods 0.000 description 6
229910052717 sulfur Chemical group 0.000 description 6
239000011593 sulfur Chemical group 0.000 description 6
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical group [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 5
239000004677 Nylon Substances 0.000 description 5
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 5
239000000010 aprotic solvent Substances 0.000 description 5
239000003054 catalyst Substances 0.000 description 5
238000010828 elution Methods 0.000 description 5
239000000284 extract Substances 0.000 description 5
238000007327 hydrogenolysis reaction Methods 0.000 description 5
229910052744 lithium Inorganic materials 0.000 description 5
229910052943 magnesium sulfate Inorganic materials 0.000 description 5
235000019341 magnesium sulphate Nutrition 0.000 description 5
229920001778 nylon Polymers 0.000 description 5
XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
229920006395 saturated elastomer Polymers 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 4
102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 4
238000005481 NMR spectroscopy Methods 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
239000012298 atmosphere Substances 0.000 description 4
239000002585 base Substances 0.000 description 4
UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 4
230000003197 catalytic effect Effects 0.000 description 4
238000005984 hydrogenation reaction Methods 0.000 description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
150000002466 imines Chemical class 0.000 description 4
239000010410 layer Substances 0.000 description 4
125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 4
238000010898 silica gel chromatography Methods 0.000 description 4
239000007858 starting material Substances 0.000 description 4
239000011550 stock solution Substances 0.000 description 4
108091007196 stromelysin Proteins 0.000 description 4
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
239000012981 Hank's balanced salt solution Substances 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
235000019270 ammonium chloride Nutrition 0.000 description 3
238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
230000005284 excitation Effects 0.000 description 3
150000002443 hydroxylamines Chemical class 0.000 description 3
239000011777 magnesium Chemical group 0.000 description 3
229910052749 magnesium Inorganic materials 0.000 description 3
229910000029 sodium carbonate Inorganic materials 0.000 description 3
WXUOEIRUBILDKO-RFZPGFLSSA-N (2r,4r)-piperidine-2,4-dicarboxylic acid Chemical compound OC(=O)[C@@H]1CCN[C@@H](C(O)=O)C1 WXUOEIRUBILDKO-RFZPGFLSSA-N 0.000 description 2
QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 description 2
KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
102100027995 Collagenase 3 Human genes 0.000 description 2
108050005238 Collagenase 3 Proteins 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
244000068988 Glycine max Species 0.000 description 2
235000010469 Glycine max Nutrition 0.000 description 2
241000282412 Homo Species 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical group [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
101710162629 Trypsin inhibitor Proteins 0.000 description 2
229940122618 Trypsin inhibitor Drugs 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
125000002252 acyl group Chemical group 0.000 description 2
125000004442 acylamino group Chemical group 0.000 description 2
229910052784 alkaline earth metal Inorganic materials 0.000 description 2
125000000304 alkynyl group Chemical group 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000011575 calcium Substances 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
239000011651 chromium Substances 0.000 description 2
239000012043 crude product Substances 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000004210 ether based solvent Substances 0.000 description 2
PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 2
239000007789 gas Substances 0.000 description 2
238000000099 in vitro assay Methods 0.000 description 2
SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 2
GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
229940040692 lithium hydroxide monohydrate Drugs 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000463 material Substances 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
239000012038 nucleophile Substances 0.000 description 2
PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 2
239000013641 positive control Substances 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
125000004076 pyridyl group Chemical group 0.000 description 2
238000006268 reductive amination reaction Methods 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
238000007127 saponification reaction Methods 0.000 description 2
WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
159000000000 sodium salts Chemical class 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000011877 solvent mixture Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000006277 sulfonation reaction Methods 0.000 description 2
239000002753 trypsin inhibitor Substances 0.000 description 2
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
APVDABVJHNBMMJ-ZWKOTPCHSA-N (2R,3S)-1-[4-[(4-fluorophenyl)methoxy]phenyl]sulfonyl-3-hydroxypiperidine-2-carboxylic acid Chemical compound FC1=CC=C(COC2=CC=C(C=C2)S(=O)(=O)N2[C@H]([C@H](CCC2)O)C(=O)O)C=C1 APVDABVJHNBMMJ-ZWKOTPCHSA-N 0.000 description 1
OPBIKRUTAUYMQB-ZWKOTPCHSA-N (2R,3S)-3-hydroxy-1-[4-(2-pyridin-4-ylethoxy)phenyl]sulfonylpiperidine-2-carboxylic acid Chemical compound O[C@@H]1[C@@H](N(CCC1)S(=O)(=O)C1=CC=C(C=C1)OCCC1=CC=NC=C1)C(=O)O OPBIKRUTAUYMQB-ZWKOTPCHSA-N 0.000 description 1
KLMWXVQCKGVNPE-RDJZCZTQSA-N (2R,3S)-3-hydroxy-3-methyl-1-[4-(1,3-thiazol-5-ylmethoxy)phenyl]sulfonylpiperidine-2-carboxylic acid Chemical compound OC(=O)[C@H]1[C@@](C)(O)CCCN1S(=O)(=O)C(C=C1)=CC=C1OCC1=CN=CS1 KLMWXVQCKGVNPE-RDJZCZTQSA-N 0.000 description 1
FWQTWUAPHQRWQB-FPOVZHCZSA-N (2R,3S)-3-hydroxy-3-methyl-1-[4-[[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]methoxy]phenyl]sulfonylpiperidine-2-carboxylic acid Chemical compound O[C@@]1([C@@H](N(CCC1)S(=O)(=O)C1=CC=C(C=C1)OCC=1SC2=C(N1)C=C(C=C2)C(F)(F)F)C(=O)O)C FWQTWUAPHQRWQB-FPOVZHCZSA-N 0.000 description 1
ZOUQAFFOFJNJLN-BXKDBHETSA-N (2R,4R)-1-(4-methoxyphenyl)sulfonylpiperidine-2,4-dicarboxylic acid Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1[C@@H](C(O)=O)C[C@H](C(O)=O)CC1 ZOUQAFFOFJNJLN-BXKDBHETSA-N 0.000 description 1
VRJFNEVMKUXFFW-VWNXMTODSA-N (2R,4S)-4-(butylaminomethyl)-4-hydroxy-1-(4-phenylmethoxyphenyl)sulfonylpiperidine-2-carboxylic acid Chemical compound OC(=O)[C@H]1C[C@@](CNCCCC)(O)CCN1S(=O)(=O)C(C=C1)=CC=C1OCC1=CC=CC=C1 VRJFNEVMKUXFFW-VWNXMTODSA-N 0.000 description 1
XAFKOOKIABRJOO-YRZWDFBDSA-N (2R,4S)-6-methoxypiperidine-1,2,4-tricarboxylic acid Chemical compound COC1C[C@@H](C(O)=O)C[C@H](C(O)=O)N1C(O)=O XAFKOOKIABRJOO-YRZWDFBDSA-N 0.000 description 1
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
KLOLSDPPPWZUNF-IAQYHMDHSA-N (2r,4r)-2-(hydroxycarbamoyl)-1-[4-(1,3-thiazol-5-ylmethoxy)phenyl]sulfonylpiperidine-4-carboxylic acid Chemical compound ONC(=O)[C@H]1C[C@H](C(O)=O)CCN1S(=O)(=O)C(C=C1)=CC=C1OCC1=CN=CS1 KLOLSDPPPWZUNF-IAQYHMDHSA-N 0.000 description 1
ZJUWKHYEAIJQFV-RHSMWYFYSA-N (2r,4r)-2-(hydroxycarbamoyl)-1-[4-(pyridin-4-ylmethoxy)phenyl]sulfonylpiperidine-4-carboxylic acid Chemical compound ONC(=O)[C@H]1C[C@H](C(O)=O)CCN1S(=O)(=O)C(C=C1)=CC=C1OCC1=CC=NC=C1 ZJUWKHYEAIJQFV-RHSMWYFYSA-N 0.000 description 1
TWPGMFKIQWDGKB-CQSZACIVSA-N 1-o-tert-butyl 5-o-methyl (2r)-2-(phenylmethoxycarbonylamino)pentanedioate Chemical compound COC(=O)CC[C@H](C(=O)OC(C)(C)C)NC(=O)OCC1=CC=CC=C1 TWPGMFKIQWDGKB-CQSZACIVSA-N 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
HATLZQXBVKJRIA-UHFFFAOYSA-N 2-(4-fluorophenyl)benzenesulfonyl chloride Chemical compound C1=CC(F)=CC=C1C1=CC=CC=C1S(Cl)(=O)=O HATLZQXBVKJRIA-UHFFFAOYSA-N 0.000 description 1
VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
VMQMRDKTYNPAFJ-UHFFFAOYSA-N 3,4-dimethylthiomorpholine-3-carboxylic acid Chemical compound CC1(N(CCSC1)C)C(=O)O VMQMRDKTYNPAFJ-UHFFFAOYSA-N 0.000 description 1
GVJJIQVNWOGRNL-UHFFFAOYSA-N 3-(4-fluorophenoxy)propane-1-sulfonyl chloride Chemical compound FC1=CC=C(OCCCS(Cl)(=O)=O)C=C1 GVJJIQVNWOGRNL-UHFFFAOYSA-N 0.000 description 1
NCQJBPXXRXOIJD-UHFFFAOYSA-N 3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-naphthalen-2-ylpropanoic acid Chemical compound C1=CC=CC2=CC(C(CC(O)=O)NC(=O)OC(C)(C)C)=CC=C21 NCQJBPXXRXOIJD-UHFFFAOYSA-N 0.000 description 1
KBRSJPHSCOAFDR-UHFFFAOYSA-N 3-chloro-6-methyl-5,5-dioxo-11h-benzo[c][2,1]benzothiazepin-11-ol Chemical compound O=S1(=O)N(C)C2=CC=CC=C2C(O)C2=CC=C(Cl)C=C21 KBRSJPHSCOAFDR-UHFFFAOYSA-N 0.000 description 1
ATVJXMYDOSMEPO-UHFFFAOYSA-N 3-prop-2-enoxyprop-1-ene Chemical compound C=CCOCC=C ATVJXMYDOSMEPO-UHFFFAOYSA-N 0.000 description 1
DAABFHOAKKNNRE-UHFFFAOYSA-N 4-[(4-fluorophenyl)methoxy]benzenesulfonyl chloride Chemical compound C1=CC(F)=CC=C1COC1=CC=C(S(Cl)(=O)=O)C=C1 DAABFHOAKKNNRE-UHFFFAOYSA-N 0.000 description 1
RHMPLDJJXGPMEX-UHFFFAOYSA-N 4-fluorophenol Chemical compound OC1=CC=C(F)C=C1 RHMPLDJJXGPMEX-UHFFFAOYSA-N 0.000 description 1
102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
208000020084 Bone disease Diseases 0.000 description 1
FDEAEOBQZKHABK-HNNXBMFYSA-N CC1([C@@H](N(CCO1)S(=O)(=O)C1=CC=C(C=C1)OCC1=CN=CS1)C(=O)O)C Chemical compound CC1([C@@H](N(CCO1)S(=O)(=O)C1=CC=C(C=C1)OCC1=CN=CS1)C(=O)O)C FDEAEOBQZKHABK-HNNXBMFYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical group [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
238000005821 Claisen rearrangement reaction Methods 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical group [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
108010026132 Gelatinases Proteins 0.000 description 1
102000013382 Gelatinases Human genes 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
VCDNHBNNPCDBKV-DLOVCJGASA-N His-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N VCDNHBNNPCDBKV-DLOVCJGASA-N 0.000 description 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
102000005741 Metalloproteases Human genes 0.000 description 1
108010006035 Metalloproteases Proteins 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical group SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 1
229910003844 NSO2 Inorganic materials 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
102100030416 Stromelysin-1 Human genes 0.000 description 1
101710108790 Stromelysin-1 Proteins 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
AVPMRIWGOGRNBF-UHFFFAOYSA-N [bromo(fluoro)methyl]benzene Chemical compound FC(Br)C1=CC=CC=C1 AVPMRIWGOGRNBF-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
239000003513 alkali Substances 0.000 description 1
125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
150000001540 azides Chemical class 0.000 description 1
210000002469 basement membrane Anatomy 0.000 description 1
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 1
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
229960003563 calcium carbonate Drugs 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
ZMIGMASIKSOYAM-UHFFFAOYSA-N cerium Chemical compound [Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce] ZMIGMASIKSOYAM-UHFFFAOYSA-N 0.000 description 1
WXANAQMHYPHTGY-UHFFFAOYSA-N cerium;ethyne Chemical compound [Ce].[C-]#[C] WXANAQMHYPHTGY-UHFFFAOYSA-N 0.000 description 1
IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
229910052804 chromium Chemical group 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000004040 coloring Methods 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Chemical group 0.000 description 1
125000004093 cyano group Chemical group *C#N 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
229960003067 cystine Drugs 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
229910001873 dinitrogen Inorganic materials 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical class CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
238000001879 gelation Methods 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229960002449 glycine Drugs 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
229910000041 hydrogen chloride Inorganic materials 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
229960002591 hydroxyproline Drugs 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
230000009545 invasion Effects 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
125000005956 isoquinolyl group Chemical group 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
BRMYZIKAHFEUFJ-UHFFFAOYSA-L mercury diacetate Chemical compound CC(=O)O[Hg]OC(C)=O BRMYZIKAHFEUFJ-UHFFFAOYSA-L 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
238000006396 nitration reaction Methods 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
ZDNNDTUAVSQNGB-UHFFFAOYSA-N o-(2-trimethylsilylethyl)hydroxylamine;hydrochloride Chemical compound Cl.C[Si](C)(C)CCON ZDNNDTUAVSQNGB-UHFFFAOYSA-N 0.000 description 1
HYDZPXNVHXJHBG-UHFFFAOYSA-N o-benzylhydroxylamine;hydron;chloride Chemical compound Cl.NOCC1=CC=CC=C1 HYDZPXNVHXJHBG-UHFFFAOYSA-N 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
238000003359 percent control normalization Methods 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
HXEACLLIILLPRG-UHFFFAOYSA-N pipecolic acid Chemical compound OC(=O)C1CCCCN1 HXEACLLIILLPRG-UHFFFAOYSA-N 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
108010052605 prostromelysin Proteins 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
238000010791 quenching Methods 0.000 description 1
125000005493 quinolyl group Chemical group 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229960001790 sodium citrate Drugs 0.000 description 1
235000011083 sodium citrates Nutrition 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
GASFYQFDNVFYQD-UHFFFAOYSA-M sodium;4-[(4-fluorophenyl)methoxy]benzenesulfonate Chemical compound [Na+].C1=CC(S(=O)(=O)[O-])=CC=C1OCC1=CC=C(F)C=C1 GASFYQFDNVFYQD-UHFFFAOYSA-M 0.000 description 1
WZWGGYFEOBVNLA-UHFFFAOYSA-N sodium;dihydrate Chemical compound O.O.[Na] WZWGGYFEOBVNLA-UHFFFAOYSA-N 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
238000012360 testing method Methods 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
GINSRDSEEGBTJO-UHFFFAOYSA-N thietane 1-oxide Chemical compound O=S1CCC1 GINSRDSEEGBTJO-UHFFFAOYSA-N 0.000 description 1
JOKIQGQOKXGHDV-UHFFFAOYSA-N thiomorpholine-3-carboxylic acid Chemical compound [O-]C(=O)C1CSCC[NH2+]1 JOKIQGQOKXGHDV-UHFFFAOYSA-N 0.000 description 1
125000003944 tolyl group Chemical group 0.000 description 1
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
230000006433 tumor necrosis factor production Effects 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
239000004474 valine Substances 0.000 description 1
230000029663 wound healing Effects 0.000 description 1
239000011592 zinc chloride Substances 0.000 description 1
235000005074 zinc chloride Nutrition 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Rheumatology (AREA)
Virology (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Hematology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Hydrogenated Pyridines (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

APAP/P/1998/001179A 1997-02-11 1998-02-05 Arylsulfonyl hydroxamic acid derivatives. AP958A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US3760097P	1997-02-11	1997-02-11

Publications (1)

Publication Number	Publication Date
AP958A true AP958A (en)	2001-04-17

Family

ID=21895216

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
APAP/P/1998/001179A AP958A (en)	1997-02-11	1998-02-05	Arylsulfonyl hydroxamic acid derivatives.

Country Status (37)

Country	Link
US (1)	US6599890B1 (id)
EP (1)	EP0960098A1 (id)
JP (1)	JP3710489B2 (id)
KR (1)	KR20000070923A (id)
CN (1)	CN1247531A (id)
AP (1)	AP958A (id)
AR (1)	AR011123A1 (id)
AU (1)	AU722784B2 (id)
BG (1)	BG63430B1 (id)
BR (1)	BR9807678A (id)
CA (1)	CA2280151C (id)
CO (1)	CO4950619A1 (id)
DZ (1)	DZ2416A1 (id)
EA (1)	EA002546B1 (id)
GT (1)	GT199800026A (id)
HN (1)	HN1998000020A (id)
HR (1)	HRP980070B1 (id)
HU (1)	HUP0000657A3 (id)
ID (1)	ID22809A (id)
IL (1)	IL131123A0 (id)
IS (1)	IS5130A (id)
MA (1)	MA24469A1 (id)
NO (1)	NO993836L (id)
NZ (1)	NZ336836A (id)
OA (1)	OA11142A (id)
PA (1)	PA8446101A1 (id)
PE (1)	PE58699A1 (id)
PL (1)	PL334997A1 (id)
SA (1)	SA98180856A (id)
SK (1)	SK101399A3 (id)
TN (1)	TNSN98025A1 (id)
TR (1)	TR199901926T2 (id)
TW (1)	TW502020B (id)
UY (1)	UY24880A1 (id)
WO (1)	WO1998034918A1 (id)
YU (1)	YU37499A (id)
ZA (1)	ZA981061B (id)

Families Citing this family (313)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR9807678A (pt) *	1997-02-11	2000-02-15	Pfizer	Derivados de ácidos arilsulfonil-hidroxâmicos
JP2002514647A (ja)	1998-05-14	2002-05-21	デュポンファーマシューティカルズカンパニー	メタロプロテイナーゼ阻害薬としての新規な置換アリールヒドロキサム酸
UA59453C2 (uk) *	1998-08-12	2003-09-15	Пфайзер Продактс Інк.	Похідні гідроксипіпеколат гідроксамової кислоти як інгібітори матричних металопротеїназ
AU4925099A (en) *	1998-08-12	2000-03-06	Pfizer Products Inc.	Tace inhibitors
AU6228499A (en) *	1998-10-22	2000-05-08	Akzo Nobel N.V.	Tetrahydropyridopyridine derivatives and intermediates for producing the same
US6326516B1 (en)	1999-01-27	2001-12-04	American Cyanamid Company	Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
US6753337B2 (en)	1999-01-27	2004-06-22	Wyeth Holdings Corporation	Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6340691B1 (en)	1999-01-27	2002-01-22	American Cyanamid Company	Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US6946473B2 (en)	1999-01-27	2005-09-20	Wyeth Holdings Corporation	Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6762178B2 (en)	1999-01-27	2004-07-13	Wyeth Holdings Corporation	Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6313123B1 (en)	1999-01-27	2001-11-06	American Cyanamid Company	Acetylenic sulfonamide thiol tace inhibitors
CN1178915C (zh)	1999-01-27	2004-12-08	惠氏控股有限公司	含有炔基的异羟肟酸衍生物、其制备及其作为基质金属蛋白酶抑制剂/TNF-α转变酶抑制剂的用途
US6277885B1 (en)	1999-01-27	2001-08-21	American Cyanamid Company	Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6200996B1 (en)	1999-01-27	2001-03-13	American Cyanamid Company	Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6225311B1 (en)	1999-01-27	2001-05-01	American Cyanamid Company	Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
EP1081137A1 (en)	1999-08-12	2001-03-07	Pfizer Products Inc.	Selective inhibitors of aggrecanase in osteoarthritis treatment
UA74803C2 (uk)	1999-11-11	2006-02-15	Осі Фармасьютікалз, Інк.	Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US6462063B1 (en)	2000-02-04	2002-10-08	Fibrogen, Inc.	C-proteinase inhibitors
US6458822B2 (en)	2000-03-13	2002-10-01	Pfizer Inc.	2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases
EP1138680A1 (en) *	2000-03-29	2001-10-04	Pfizer Products Inc.	Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
GB0011409D0 (en) *	2000-05-11	2000-06-28	Smithkline Beecham Plc	Novel compounds
JP2001322977A (ja) *	2000-05-12	2001-11-20	Kotobuki Seiyaku Kk	ピペコリン酸誘導体及びその製造方法並びにこれを含有する医薬組成物
EP2796468A2 (en)	2001-01-05	2014-10-29	Pfizer Inc	Antibodies to insulin-like growth factor I receptor
MXPA01013172A (es)	2001-02-14	2002-08-21	Warner Lambert Co	Inhibidores sulfonamida de metaloproteinasa de matriz.
MXPA01013326A (es) *	2001-02-14	2002-08-26	Warner Lambert Co	Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz.
MXPA01013171A (es)	2001-02-14	2004-05-21	Warner Lambert Co	Inhibidores triciclicos de sulfonamida de metaloproteinasa de matriz.
US6995171B2 (en)	2001-06-21	2006-02-07	Agouron Pharmaceuticals, Inc.	Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents
AUPR726201A0 (en) *	2001-08-24	2001-09-20	Fujisawa Pharmaceutical Co., Ltd.	New use of a cyclic compound
MXPA04004010A (es)	2001-11-01	2004-07-23	Wyeth Corp	Acidos hidroxamicos de aril sulfonamida alenicos como inhibidores de tace y metaloproteinasa de matriz.
AR039067A1 (es)	2001-11-09	2005-02-09	Pfizer Prod Inc	Anticuerpos para cd40
BR0308162A (pt)	2002-03-01	2004-12-07	Pfizer	Derivados de indolil-uréia de tienopiridinas úteis como agentes antiangiogênicos e métodos para o seu uso
DE60330227D1 (de)	2002-03-13	2010-01-07	Array Biopharma Inc	N3-alkylierte benzimidazol-derivate als mek-hemmer
US7629341B2 (en)	2002-06-12	2009-12-08	Symphony Evolution, Inc.	Human ADAM-10 inhibitors
UA77303C2 (en)	2002-06-14	2006-11-15	Pfizer	Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
PL377713A1 (pl)	2002-12-19	2006-02-06	Pfizer Inc.	Związki 2-(1H-indazol-6-iloamino)benzamidowe jako inhibitory kinaz białkowych użyteczne w leczeniu chorób oczu
US7199155B2 (en)	2002-12-23	2007-04-03	Wyeth Holdings Corporation	Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
GEP20084341B (en)	2003-02-26	2008-03-25	Sugen Inc	Aminoheteroaryl compounds as protein kinase inhibitors
HN2004000285A (es)	2003-08-04	2006-04-27	Pfizer Prod Inc	ANTICUERPOS DIRIGIDOS A c-MET
EP1660504B1 (en)	2003-08-29	2008-10-29	Pfizer Inc.	Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents
US7144907B2 (en)	2003-09-03	2006-12-05	Array Biopharma Inc.	Heterocyclic inhibitors of MEK and methods of use thereof
AR045563A1 (es)	2003-09-10	2005-11-02	Warner Lambert Co	Anticuerpos dirigidos a m-csf
CN1905873A (zh)	2003-11-19	2007-01-31	阵列生物制药公司	Mek的杂环抑制剂及其使用方法
GT200500139A (es)	2004-06-08	2005-07-25		Metodo para la preparacion de acidos hidroxamicos
WO2006008639A1 (en)	2004-07-16	2006-01-26	Pfizer Products Inc.	Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
BRPI0513915A (pt)	2004-08-26	2008-05-20	Pfizer	compostos aminoeteroarila enantiomericamente puros como inibidores de proteìna quinase
MY146381A (en)	2004-12-22	2012-08-15	Amgen Inc	Compositions and methods relating relating to anti-igf-1 receptor antibodies
US7429667B2 (en)	2005-01-20	2008-09-30	Ardea Biosciences, Inc.	Phenylamino isothiazole carboxamidines as MEK inhibitors
US8299076B2 (en)	2005-05-18	2012-10-30	Array Biopharma Inc.	Crystalline forms of 2-(2-flouro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide
US7897624B2 (en)	2006-04-18	2011-03-01	Ardea Biosciences	Pyridone sulfonamides and pyridone sulfamides as MEK inhibitors
US8101799B2 (en)	2005-07-21	2012-01-24	Ardea Biosciences	Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
EP1926996B1 (en)	2005-09-20	2011-11-09	OSI Pharmaceuticals, Inc.	Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
TWI405756B (zh)	2005-12-21	2013-08-21	Array Biopharma Inc	新穎硫酸氫鹽
US7842836B2 (en)	2006-04-11	2010-11-30	Ardea Biosciences	N-aryl-N'alkyl sulfamides as MEK inhibitors
EP2121626A1 (en)	2006-12-15	2009-11-25	Pfizer Products Inc.	Benzimidazole derivatives
AU2008206045A1 (en)	2007-01-19	2008-07-24	Ardea Biosciences, Inc.	Inhibitors of MEK
DK2146779T3 (en)	2007-04-18	2016-11-28	Pfizer Prod Inc	Sulfonylamid derivatives to treat abnormal cell growth.
US8530463B2 (en)	2007-05-07	2013-09-10	Hale Biopharma Ventures Llc	Multimodal particulate formulations
CA2924436A1 (en)	2007-07-30	2009-02-05	Ardea Biosciences, Inc.	Pharmaceutical combinations of n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide as inhibitors of mek and methods of use
EP2690101B1 (en)	2007-12-19	2015-06-24	Genentech, Inc.	5-Anilinoimidazopyridines and Methods of Use
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
AU2009204483B2 (en)	2008-01-04	2014-03-13	Intellikine, Llc	Certain chemical entities, compositions and methods
JP5547099B2 (ja)	2008-03-14	2014-07-09	インテリカイン，エルエルシー	キナーゼ阻害剤および使用方法
ES2586032T3 (es)	2008-03-28	2016-10-11	Hale Biopharma Ventures, Llc	Administración de composiciones de benzodiazepinas
MX2011000216A (es)	2008-07-08	2011-03-29	Intellikine Inc	Inhibidores de cinasa y metodos para su uso.
WO2010045495A2 (en)	2008-10-16	2010-04-22	University Of Pittsburgh-Of The Commonwealth System Of Higher Education	Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
US8476431B2 (en)	2008-11-03	2013-07-02	Itellikine LLC	Benzoxazole kinase inhibitors and methods of use
SG173152A1 (en)	2009-02-05	2011-08-29	Immunogen Inc	Novel benzodiazepine derivatives
CA2748943A1 (en)	2009-02-09	2010-08-12	Supergen, Inc.	Pyrrolopyrimidinyl axl kinase inhibitors
EP2400985A2 (en)	2009-02-25	2012-01-04	OSI Pharmaceuticals, LLC	Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
JP2012519170A (ja)	2009-02-26	2012-08-23	オーエスアイ・ファーマシューティカルズ，エルエルシー	生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法
EP2401614A1 (en)	2009-02-27	2012-01-04	OSI Pharmaceuticals, LLC	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010098866A1 (en)	2009-02-27	2010-09-02	Supergen, Inc.	Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
WO2010099138A2 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519282A (ja)	2009-02-27	2012-08-23	オーエスアイ・ファーマシューティカルズ，エルエルシー	間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
ES2543608T3 (es)	2009-03-27	2015-08-20	Ardea Biosciences, Inc.	Dihidropiridin sulfonamidas y dihidropiridin sulfamidas como inhibidores de MEK
WO2010129816A2 (en)	2009-05-07	2010-11-11	Intellikine, Inc.	Heterocyclic compounds and uses thereof
US20120128670A1 (en)	2009-07-31	2012-05-24	OSI Pharmaceuticals, LLC	mTOR INHIBITOR AND ANGIOGENESIS INHIBITOR COMBINATION THERAPY
GEP201706639B (en)	2009-08-17	2017-03-27	Intellikine Llc	Heterocyclic compounds and uses thereof
JP2013503846A (ja)	2009-09-01	2013-02-04	ファイザー・インク	ベンズイミダゾール誘導体
US9034861B2 (en)	2009-10-13	2015-05-19	Allomek Therapeutics Llc	MEK inhibitors useful in the treatment of diseases
WO2011049625A1 (en)	2009-10-20	2011-04-28	Mansour Samadpour	Method for aflatoxin screening of products
PT2496567T (pt)	2009-11-05	2017-11-15	Rhizen Pharmaceuticals S A	Novos moduladores de quinase benzopiran
WO2011100403A1 (en)	2010-02-10	2011-08-18	Immunogen, Inc	Cd20 antibodies and uses thereof
RS55487B2 (sr)	2010-02-12	2024-06-28	Pfizer	Soli i polimorfi 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona
AU2011223655A1 (en)	2010-03-03	2012-06-28	OSI Pharmaceuticals, LLC	Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2519826A2 (en)	2010-03-03	2012-11-07	OSI Pharmaceuticals, LLC	Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
ES2715611T3 (es)	2010-05-17	2019-06-05	Incozen Therapeutics Pvt Ltd	Compuestos novedosos de 3H-imidazo[4,5-b]piridina-3,5-disustituida y 3H-[1,2,3]triazolo[4,5-b]piridina 3,5-disustituida como moduladores de proteína cinasas
JP5951600B2 (ja)	2010-05-21	2016-07-13	インフィニティーファーマシューティカルズ，インコーポレイテッド	キナーゼ調節のための、化合物、組成物および方法
JP2013538042A (ja)	2010-06-16	2013-10-10	ユニバーシティオブピッツバーグ − オブザコモンウェルスシステムオブハイヤーエデュケイション	エンドプラスミンに対する抗体およびその使用
WO2012052948A1 (en)	2010-10-20	2012-04-26	Pfizer Inc.	Pyridine- 2- derivatives as smoothened receptor modulators
US8901133B2 (en)	2010-11-10	2014-12-02	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
KR20180080358A (ko)	2011-01-10	2018-07-11	인피니티 파마슈티칼스, 인코포레이티드	이소퀴놀린온 및 이의 고체 형태의 제조 방법
US20140037642A1 (en)	2011-02-02	2014-02-06	Amgen Inc.	Methods and compositions relating to inhibition of igf-1r
KR20190089048A (ko)	2011-02-15	2019-07-29	이뮤노젠 아이엔씨	컨쥬게이트의 제조방법
WO2012116040A1 (en)	2011-02-22	2012-08-30	OSI Pharmaceuticals, LLC	Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
JP5808826B2 (ja)	2011-02-23	2015-11-10	インテリカイン，エルエルシー	複素環化合物およびその使用
US9150644B2 (en)	2011-04-12	2015-10-06	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
US20140178368A1 (en)	2011-04-19	2014-06-26	Leslie Lynne SHARP	Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
US9896730B2 (en)	2011-04-25	2018-02-20	OSI Pharmaceuticals, LLC	Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
RS58326B1 (sr)	2011-05-04	2019-03-29	Rhizen Pharmaceuticals S A	Nova jedinjenja kao modulatori proteinskih kinaza
CN103796656A (zh)	2011-06-14	2014-05-14	哈尔生物药投资有限责任公司	苯二氮卓的投与
CN103930422A (zh)	2011-07-19	2014-07-16	无限药品股份有限公司	杂环化合物及其用途
EP2734530A1 (en)	2011-07-19	2014-05-28	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
PL3409278T3 (pl)	2011-07-21	2021-02-22	Sumitomo Pharma Oncology, Inc.	Heterocykliczne inhibitory kinazy białkowej
CN103998442B (zh)	2011-08-29	2016-09-14	无限药品股份有限公司	杂环化合物及其用途
MD20140023A2 (ro)	2011-09-22	2014-06-30	Pfizer Inc.	Derivaţi de pirolpirimidină şi purină
US9630979B2 (en)	2011-09-29	2017-04-25	Infinity Pharmaceuticals, Inc.	Inhibitors of monoacylglycerol lipase and methods of their use
CN103998435A (zh) *	2011-10-04	2014-08-20	法国国家健康医疗研究院	新型细胞凋亡诱导化合物
AU2011378675B2 (en)	2011-10-04	2017-10-05	Epsilogen Ltd	IgE anti -HMW-MAA antibody
RU2014114015A (ru)	2011-11-08	2015-12-20	Пфайзер Инк.	Способы лечения воспалительных расстройств с использованием антител против m-csf
ES2668044T3 (es)	2012-02-22	2018-05-16	The Regents Of The University Of Colorado, A Body Corporate	Derivados de bouvardina y usos terapéuticos de los mismos
US9452215B2 (en)	2012-02-22	2016-09-27	The Regents Of The University Of Colorado	Bourvadin derivatives and therapeutic uses thereof
CN107082779A (zh)	2012-03-30	2017-08-22	理森制药股份公司	作为c‑met 蛋白激酶调节剂的新化合物
WO2013152252A1 (en)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
ES2718478T3 (es)	2012-06-08	2019-07-02	Sutro Biopharma Inc	Anticuerpos que comprenden restos de aminoácidos no naturales de localización específica, métodos para su preparación y métodos para su uso
DK2863955T3 (en)	2012-06-26	2017-01-23	Sutro Biopharma Inc	MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
EP2887965A1 (en)	2012-08-22	2015-07-01	ImmunoGen, Inc.	Cytotoxic benzodiazepine derivatives
SG11201501464TA (en)	2012-08-31	2015-03-30	Sutro Biopharma Inc	Modified amino acids comprising an azido group
WO2014062838A2 (en)	2012-10-16	2014-04-24	Tolero Pharmaceuticals, Inc.	Pkm2 modulators and methods for their use
IL291945B2 (en)	2012-11-01	2025-11-01	Infinity Pharmaceuticals Inc	Treatment of cancers using pi3 kinase isoform modulators
US9901647B2 (en)	2013-02-28	2018-02-27	Immunogen, Inc.	Conjugates comprising cell-binding agents and cytotoxic agents
WO2014134483A2 (en)	2013-02-28	2014-09-04	Immunogen, Inc.	Conjugates comprising cell-binding agents and cytotoxic agents
RU2693480C2 (ru)	2013-03-14	2019-07-03	Толеро Фармасьютикалз, Инк.	Ингибиторы jak2 и alk2 и способы их использования
WO2014151386A1 (en)	2013-03-15	2014-09-25	Infinity Pharmaceuticals, Inc.	Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
EP2970121B1 (en)	2013-03-15	2017-12-13	Araxes Pharma LLC	Covalent inhibitors of kras g12c
US9227978B2 (en)	2013-03-15	2016-01-05	Araxes Pharma Llc	Covalent inhibitors of Kras G12C
WO2014151147A1 (en)	2013-03-15	2014-09-25	Intellikine, Llc	Combination of kinase inhibitors and uses thereof
WO2014143659A1 (en)	2013-03-15	2014-09-18	Araxes Pharma Llc	Irreversible covalent inhibitors of the gtpase k-ras g12c
SG10201709926VA (en)	2013-05-30	2017-12-28	Infinity Pharmaceuticals Inc	Treatment of cancers using pi3 kinase isoform modulators
WO2014194030A2 (en)	2013-05-31	2014-12-04	Immunogen, Inc.	Conjugates comprising cell-binding agents and cytotoxic agents
US9764039B2 (en)	2013-07-10	2017-09-19	Sutro Biopharma, Inc.	Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
JP6427197B2 (ja)	2013-10-03	2018-11-21	クラオンコロジー，インコーポレイテッド	Ｅｒｋの阻害剤および使用方法
WO2015051241A1 (en)	2013-10-04	2015-04-09	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
MX389256B (es)	2013-10-04	2025-03-20	Infinity Pharmaceuticals Inc	Compuestos heterociclicos y usos de los mismos.
JO3805B1 (ar)	2013-10-10	2021-01-31	Araxes Pharma Llc	مثبطات كراس جي12سي
EP3636639A1 (en)	2013-10-10	2020-04-15	Araxes Pharma LLC	Inhibitors of kras g12c
WO2015054658A1 (en)	2013-10-11	2015-04-16	Sutro Biopharma, Inc.	Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
US20160244452A1 (en)	2013-10-21	2016-08-25	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
UA115388C2 (uk)	2013-11-21	2017-10-25	Пфайзер Інк.	2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
WO2015155624A1 (en)	2014-04-10	2015-10-15	Pfizer Inc.	Dihydropyrrolopyrimidine derivatives
WO2015168079A1 (en)	2014-04-29	2015-11-05	Infinity Pharmaceuticals, Inc.	Pyrimidine or pyridine derivatives useful as pi3k inhibitors
WO2015166373A1 (en)	2014-04-30	2015-11-05	Pfizer Inc.	Cycloalkyl-linked diheterocycle derivatives
PE20170268A1 (es)	2014-06-19	2017-04-21	Ariad Pharma Inc	Compuestos de heteroarilo para la inhibicion de cinasa
WO2016001789A1 (en)	2014-06-30	2016-01-07	Pfizer Inc.	Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
ES2848857T3 (es)	2014-07-31	2021-08-12	Us Gov Health & Human Services	Anticuerpos monoclonales humanos contra EphA4 y su uso
JO3556B1 (ar)	2014-09-18	2020-07-05	Araxes Pharma Llc	علاجات مدمجة لمعالجة السرطان
JP2017528498A (ja)	2014-09-25	2017-09-28	アラクセスファーマエルエルシー	Ｋｒａｓｇ１２ｃ変異体タンパク質のインヒビター
WO2016049568A1 (en)	2014-09-25	2016-03-31	Araxes Pharma Llc	Methods and compositions for inhibition of ras
JP6621477B2 (ja)	2014-12-18	2019-12-18	ファイザー・インク	ピリミジンおよびトリアジン誘導体ならびにａｘｌ阻害薬としてのそれらの使用
ES2898765T3 (es)	2015-04-10	2022-03-08	Araxes Pharma Llc	Compuestos de quinazolina sustituidos y métodos de uso de los mismos
ES2856880T3 (es)	2015-04-15	2021-09-28	Araxes Pharma Llc	Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos
BR112017022666A8 (pt)	2015-04-20	2022-10-18	Tolero Pharmaceuticals Inc	Preparando resposta à alvocidib por perfilamento mitocondrial
CN107709344B (zh)	2015-05-01	2022-07-15	共晶制药股份有限公司	用于治疗黄病毒科病毒和癌症的核苷类似物
CN111349118B (zh)	2015-05-18	2023-08-22	住友制药肿瘤公司	具有增加的生物利用度的阿伏西地前药
AR104020A1 (es)	2015-06-04	2017-06-21	Kura Oncology Inc	Métodos y composiciones para inhibir la interacción de menina con proteínas mill
WO2017009751A1 (en)	2015-07-15	2017-01-19	Pfizer Inc.	Pyrimidine derivatives
US10144724B2 (en)	2015-07-22	2018-12-04	Araxes Pharma Llc	Substituted quinazoline compounds and methods of use thereof
RU2759963C2 (ru)	2015-08-03	2021-11-19	Сумитомо Даиниппон Фарма Онколоджи, Инк.	Комбинированные терапии для лечения рака
CN108349985A (zh)	2015-09-14	2018-07-31	无限药品股份有限公司	异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
WO2017058792A1 (en)	2015-09-28	2017-04-06	Araxes Pharma Llc	Inhibitors of kras g12c mutant proteins
US10975071B2 (en)	2015-09-28	2021-04-13	Araxes Pharma Llc	Inhibitors of KRAS G12C mutant proteins
EP3356347A1 (en)	2015-09-28	2018-08-08	Araxes Pharma LLC	Inhibitors of kras g12c mutant proteins
US10647703B2 (en)	2015-09-28	2020-05-12	Araxes Pharma Llc	Inhibitors of KRAS G12C mutant proteins
US10689356B2 (en)	2015-09-28	2020-06-23	Araxes Pharma Llc	Inhibitors of KRAS G12C mutant proteins
EP3356353A1 (en)	2015-09-28	2018-08-08	Araxes Pharma LLC	Inhibitors of kras g12c mutant proteins
US10730867B2 (en)	2015-09-28	2020-08-04	Araxes Pharma Llc	Inhibitors of KRAS G12C mutant proteins
WO2017070256A2 (en)	2015-10-19	2017-04-27	Araxes Pharma Llc	Method for screening inhibitors of ras
US10414757B2 (en)	2015-11-16	2019-09-17	Araxes Pharma Llc	2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
JP6877429B2 (ja)	2015-12-03	2021-05-26	アジオスファーマシューティカルズ，インコーポレイテッド	Ｍｔａｐヌル癌を処置するためのｍａｔ２ａ阻害剤
US9988357B2 (en)	2015-12-09	2018-06-05	Araxes Pharma Llc	Methods for preparation of quinazoline derivatives
SG11201806419RA (en)	2016-01-27	2018-08-30	Sutro Biopharma Inc	Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
KR102419524B1 (ko)	2016-03-16	2022-07-08	쿠라 온콜로지, 인크.	메닌-mll의 가교된 이환식 억제제 및 사용 방법
BR112018068703B1 (pt)	2016-03-16	2024-02-06	Kura Oncology, Inc.	Inibidores substituídos de menin-mll e métodos de uso
WO2017172979A1 (en)	2016-03-30	2017-10-05	Araxes Pharma Llc	Substituted quinazoline compounds and methods of use
CA3024556A1 (en)	2016-05-12	2017-11-16	The Regents Of The University Of Michigan	Ash1l inhibitors and methods of treatment therewith
US11118233B2 (en)	2016-05-18	2021-09-14	The University Of Chicago	BTK mutation and ibrutinib resistance
WO2017214269A1 (en)	2016-06-08	2017-12-14	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US10646488B2 (en)	2016-07-13	2020-05-12	Araxes Pharma Llc	Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
US10870694B2 (en)	2016-09-02	2020-12-22	Dana Farber Cancer Institute, Inc.	Composition and methods of treating B cell disorders
WO2018064510A1 (en)	2016-09-29	2018-04-05	Araxes Pharma Llc	Inhibitors of kras g12c mutant proteins
US10377743B2 (en)	2016-10-07	2019-08-13	Araxes Pharma Llc	Inhibitors of RAS and methods of use thereof
US11279694B2 (en)	2016-11-18	2022-03-22	Sumitomo Dainippon Pharma Oncology, Inc.	Alvocidib prodrugs and their use as protein kinase inhibitors
WO2018098352A2 (en)	2016-11-22	2018-05-31	Jun Oishi	Targeting kras induced immune checkpoint expression
JP6619519B2 (ja)	2016-12-19	2019-12-11	トレロファーマシューティカルズ，インコーポレイテッド	プロファイリングペプチドおよび感受性プロファイリングのための方法
NZ754994A (en)	2016-12-22	2022-12-23	Amgen Inc	Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
WO2018140600A1 (en)	2017-01-26	2018-08-02	Araxes Pharma Llc	Fused hetero-hetero bicyclic compounds and methods of use thereof
WO2018137705A1 (en)	2017-01-26	2018-08-02	Zai Lab (Shanghai) Co., Ltd.	Cd47 antigen binding unit and uses thereof
EP3573954A1 (en)	2017-01-26	2019-12-04	Araxes Pharma LLC	Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
WO2018140599A1 (en)	2017-01-26	2018-08-02	Araxes Pharma Llc	Benzothiophene and benzothiazole compounds and methods of use thereof
US11136308B2 (en)	2017-01-26	2021-10-05	Araxes Pharma Llc	Substituted quinazoline and quinazolinone compounds and methods of use thereof
JP2020505395A (ja)	2017-01-26	2020-02-20	アラクセスファーマエルエルシー	縮合ｎ−複素環式化合物およびその使用方法
EP3573971A1 (en)	2017-01-26	2019-12-04	Araxes Pharma LLC	1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
US11944627B2 (en)	2017-03-24	2024-04-02	Kura Oncology, Inc.	Methods for treating hematological malignancies and Ewing's sarcoma
JOP20190272A1 (ar)	2017-05-22	2019-11-21	Amgen Inc	مثبطات kras g12c وطرق لاستخدامها
CN110869357A (zh)	2017-05-25	2020-03-06	亚瑞克西斯制药公司	化合物及其用于治疗癌症的使用方法
KR20200010306A (ko)	2017-05-25	2020-01-30	아락세스 파마 엘엘씨	Kras의 공유적 억제제
WO2018218069A1 (en)	2017-05-25	2018-11-29	Araxes Pharma Llc	Quinazoline derivatives as modulators of mutant kras, hras or nras
WO2018226976A1 (en)	2017-06-08	2018-12-13	Kura Oncology, Inc.	Methods and compositions for inhibiting the interaction of menin with mll proteins
EP3658588A1 (en)	2017-07-26	2020-06-03	Sutro Biopharma, Inc.	Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
ES2928576T3 (es)	2017-09-08	2022-11-21	Amgen Inc	Inhibidores de KRAS G12C y métodos de uso de los mismos
WO2019055579A1 (en)	2017-09-12	2019-03-21	Tolero Pharmaceuticals, Inc.	TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
KR20200051802A (ko)	2017-09-18	2020-05-13	서트로 바이오파마, 인크.	항-엽산 수용체 알파 항체 접합체 및 이의 용도
WO2019060365A1 (en)	2017-09-20	2019-03-28	Kura Oncology, Inc.	SUBSTITUTED MÉNINE-MLL INHIBITORS AND METHODS OF USE
WO2019075367A1 (en)	2017-10-13	2019-04-18	Tolero Pharmaceuticals, Inc.	PKM2 ACTIVATORS IN COMBINATION WITH OXYGEN REACTIVE SPECIES FOR THE TREATMENT OF CANCER
JP2021502388A (ja)	2017-11-10	2021-01-28	ザリージェンツオブザユニバーシティオブミシガン	Ａｓｈ１ｌ阻害剤及びそれを用いた治療方法
WO2019113469A1 (en)	2017-12-07	2019-06-13	The Regents Of The University Of Michigan	Nsd family inhibitors and methods of treatment therewith
EP3773591A4 (en)	2018-04-05	2021-12-22	Sumitomo Dainippon Pharma Oncology, Inc.	AXL KINASE INHIBITORS AND THEIR USE
CA3099118A1 (en)	2018-05-04	2019-11-07	Amgen Inc.	Kras g12c inhibitors and methods of using the same
MA52501A (fr)	2018-05-04	2021-03-10	Amgen Inc	Inhibiteurs de kras g12c et leurs procédés d'utilisation
EP3790886B1 (en)	2018-05-10	2024-06-26	Amgen Inc.	Kras g12c inhibitors for the treatment of cancer
EP3802535B1 (en)	2018-06-01	2022-12-14	Amgen, Inc	Kras g12c inhibitors and methods of using the same
US11319302B2 (en)	2018-06-07	2022-05-03	The Regents Of The University Of Michigan	PRC1 inhibitors and methods of treatment therewith
CA3099799A1 (en)	2018-06-11	2019-12-19	Amgen Inc.	Kras g12c inhibitors for treating cancer
MA51848A (fr)	2018-06-12	2021-04-21	Amgen Inc	Inhibiteurs de kras g12c et leurs procédés d'utilisation
CA3103995A1 (en)	2018-07-26	2020-01-30	Sumitomo Dainippon Pharma Oncology, Inc.	Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
CA3107168A1 (en)	2018-08-01	2020-02-06	Araxes Pharma Llc	Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
US20220047716A1 (en)	2018-09-17	2022-02-17	Sutro Biopharma, Inc.	Combination therapies with anti-folate receptor antibody conjugates
KR20210083286A (ko)	2018-10-24	2021-07-06	아락세스 파마 엘엘씨	종양 전이를 억제하기 위한 g12c 돌연변이 kras 단백질의 억제제로서 2-(2-아크릴로일-2,6-디아자스피로[3.4]옥탄-6-일)-6-(1h-인다졸-4-일)-벤조니트릴 유도체 및 관련 화합물
JP7516029B2 (ja)	2018-11-16	2024-07-16	アムジエン・インコーポレーテツド	Ｋｒａｓｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
US11053226B2 (en)	2018-11-19	2021-07-06	Amgen Inc.	KRAS G12C inhibitors and methods of using the same
JP7377679B2 (ja)	2018-11-19	2023-11-10	アムジエン・インコーポレーテツド	がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
MX2021005924A (es)	2018-11-29	2021-06-30	Araxes Pharma Llc	Compuestos y metodos de uso de los mismos para el tratamiento del cancer.
MX2021006544A (es)	2018-12-04	2021-07-07	Sumitomo Pharma Oncology Inc	Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
EA202191730A1 (ru)	2018-12-20	2021-08-24	Эмджен Инк.	Ингибиторы kif18a
MA54546A (fr)	2018-12-20	2022-03-30	Amgen Inc	Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
MA54550A (fr)	2018-12-20	2022-03-30	Amgen Inc	Inhibiteurs de kif18a
AU2019401495B2 (en)	2018-12-20	2025-06-26	Amgen Inc.	Heteroaryl amides useful as KIF18A inhibitors
NZ778055A (en)	2019-02-12	2025-11-28	Sumitomo Pharma America Inc	Formulations comprising heterocyclic protein kinase inhibitors
CN113727758A (zh)	2019-03-01	2021-11-30	锐新医药公司	双环杂环基化合物及其用途
KR20210146287A (ko)	2019-03-01	2021-12-03	레볼루션 메디슨즈, 인크.	이환식 헤테로아릴 화합물 및 이의 용도
JP2022525149A (ja)	2019-03-20	2022-05-11	スミトモダイニッポンファーマオンコロジー，インコーポレイテッド	ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
WO2020198077A1 (en)	2019-03-22	2020-10-01	Sumitomo Dainippon Pharma Oncology, Inc.	Compositions comprising pkm2 modulators and methods of treatment using the same
WO2020227105A1 (en)	2019-05-03	2020-11-12	Sutro Biopharma, Inc.	Anti-bcma antibody conjugates
EP3738593A1 (en)	2019-05-14	2020-11-18	Amgen, Inc	Dosing of kras inhibitor for treatment of cancers
EP3972973A1 (en)	2019-05-21	2022-03-30	Amgen Inc.	Solid state forms
CN114302878A (zh)	2019-07-03	2022-04-08	大日本住友制药肿瘤公司	酪氨酸激酶非受体1(tnk1)抑制剂及其用途
WO2021026098A1 (en)	2019-08-02	2021-02-11	Amgen Inc.	Kif18a inhibitors
JP7640521B2 (ja)	2019-08-02	2025-03-05	アムジエン・インコーポレーテツド	Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド
ES3051918T3 (en)	2019-08-02	2025-12-30	Amgen Inc	Kif18a inhibitors
CN114391012B (zh)	2019-08-02	2025-10-31	美国安进公司	作为kif18a抑制剂的吡啶衍生物
WO2021055728A1 (en)	2019-09-18	2021-03-25	Merck Sharp & Dohme Corp.	Small molecule inhibitors of kras g12c mutant
WO2021067215A1 (en)	2019-09-30	2021-04-08	Agios Pharmaceuticals, Inc.	Piperidine compounds as menin inhibitors
EP4048671B1 (en)	2019-10-24	2026-03-18	Amgen Inc.	Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
CR20220230A (es)	2019-10-28	2022-06-15	Merck Sharp & Dohme	Inhibidores de pequeñas moléculas de mutante g12c de kras
WO2021085653A1 (en)	2019-10-31	2021-05-06	Taiho Pharmaceutical Co., Ltd.	4-aminobut-2-enamide derivatives and salts thereof
KR20220109407A (ko)	2019-11-04	2022-08-04	레볼루션 메디슨즈, 인크.	Ras 억제제
JP7823816B2 (ja)	2019-11-04	2026-03-04	レヴォリューション・メディスンズ，インコーポレイテッド	Ｒａｓ阻害剤
EP4054719B1 (en)	2019-11-04	2026-02-11	Revolution Medicines, Inc.	Ras inhibitors
BR112022008858A2 (pt)	2019-11-08	2022-09-06	Revolution Medicines Inc	Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
WO2021097207A1 (en)	2019-11-14	2021-05-20	Amgen Inc.	Improved synthesis of kras g12c inhibitor compound
JP2023501528A (ja)	2019-11-14	2023-01-18	アムジエン・インコーポレーテツド	Ｋｒａｓｇ１２ｃ阻害剤化合物の改善された合成
WO2021108683A1 (en)	2019-11-27	2021-06-03	Revolution Medicines, Inc.	Covalent ras inhibitors and uses thereof
WO2021106231A1 (en)	2019-11-29	2021-06-03	Taiho Pharmaceutical Co., Ltd.	A compound having inhibitory activity against kras g12d mutation
CN114929279A (zh)	2020-01-07	2022-08-19	锐新医药公司	Shp2抑制剂给药和治疗癌症的方法
WO2021155006A1 (en)	2020-01-31	2021-08-05	Les Laboratoires Servier Sas	Inhibitors of cyclin-dependent kinases and uses thereof
US20230095053A1 (en)	2020-03-03	2023-03-30	Sutro Biopharma, Inc.	Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
TW202204333A (zh)	2020-04-08	2022-02-01	美商阿吉歐斯製藥公司	Menin抑制劑及治療癌症之使用方法
TW202204334A (zh)	2020-04-08	2022-02-01	美商阿吉歐斯製藥公司	Menin抑制劑及治療癌症之使用方法
WO2021215545A1 (en)	2020-04-24	2021-10-28	Taiho Pharmaceutical Co., Ltd.	Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
US20230174518A1 (en)	2020-04-24	2023-06-08	Taiho Pharmaceutical Co., Ltd.	Kras g12d protein inhibitors
CA3183032A1 (en)	2020-06-18	2021-12-23	Mallika Singh	Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
CN116113406B (zh)	2020-07-10	2025-08-29	密歇根大学董事会	Gas41抑制剂及其使用方法
EP4183395A4 (en)	2020-07-15	2024-07-24	Taiho Pharmaceutical Co., Ltd.	PYRIMIDINE COMPOUND-CONTAINING COMBINATION FOR USE IN TUMOR TREATMENT
MX2023002248A (es)	2020-09-03	2023-05-16	Revolution Medicines Inc	Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
CR20230165A (es)	2020-09-15	2023-06-02	Revolution Medicines Inc	Derivados indólicos como inhibidores de ras en el tratamiento del cáncer
TW202237119A (zh)	2020-12-10	2022-10-01	美商住友製藥腫瘤公司	Ａｌｋ﹘５抑制劑和彼之用途
CN117396472A (zh)	2020-12-22	2024-01-12	上海齐鲁锐格医药研发有限公司	Sos1抑制剂及其用途
US12037346B2 (en)	2021-04-13	2024-07-16	Nuvalent, Inc.	Amino-substituted heteroaryls for treating cancers with EGFR mutations
CN117396231A (zh)	2021-04-30	2024-01-12	新基公司	使用抗BCMA抗体药物缀合物（ADC）与γ分泌酶抑制剂（GSI）的组合的组合疗法
IL308193A (en)	2021-05-05	2024-01-01	Revolution Medicines Inc	RAS inhibitors
WO2022235866A1 (en)	2021-05-05	2022-11-10	Revolution Medicines, Inc.	Covalent ras inhibitors and uses thereof
CR20230558A (es)	2021-05-05	2024-01-24	Revolution Medicines Inc	Inhibidores de ras para el tratamiento del cáncer
CN117769554A (zh)	2021-05-28	2024-03-26	大鹏药品工业株式会社	Kras突变蛋白的小分子抑制剂
AR127308A1 (es)	2021-10-08	2024-01-10	Revolution Medicines Inc	Inhibidores ras
WO2023056589A1 (en)	2021-10-08	2023-04-13	Servier Pharmaceuticals Llc	Menin inhibitors and methods of use for treating cancer
WO2023064058A1 (en)	2021-10-12	2023-04-20	Peloton Therapeutics Inc.	Tricyclic sultams and sulfamides as antitumor agents
JP2025500878A (ja)	2021-12-17	2025-01-15	ジェンザイム・コーポレーション	Ｓｈｐ２阻害剤としてのピラゾロピラジン化合物
EP4227307A1 (en)	2022-02-11	2023-08-16	Genzyme Corporation	Pyrazolopyrazine compounds as shp2 inhibitors
IL314883A (en)	2022-03-07	2024-10-01	Amgen Inc	A process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile
CN119136806A (zh)	2022-03-08	2024-12-13	锐新医药公司	用于治疗免疫难治性肺癌的方法
TW202412755A (zh)	2022-04-25	2024-04-01	美商耐斯泰德醫療公司	促分裂原活化蛋白激酶（ｍｅｋ）抑制劑
WO2023240263A1 (en)	2022-06-10	2023-12-14	Revolution Medicines, Inc.	Macrocyclic ras inhibitors
EP4547284A1 (en)	2022-06-30	2025-05-07	Sutro Biopharma, Inc.	Anti-ror1 antibodies and antibody conjugates, compositions comprising anti-ror1 antibodies or antibody conjugates, and methods of making and using anti-ror1 antibodies and antibody conjugates
JP2025521928A (ja)	2022-07-08	2025-07-10	ネステッド・セラピューティクス・インコーポレイテッド	マイトジェン活性化プロテインキナーゼ（ｍｅｋ）阻害剤
PE20251879A1 (es)	2022-10-14	2025-07-22	Black Diamond Therapeutics Inc	Metodos de tratamiento del cancer usando derivados de isoquinolina o 6-aza-quinolina
AU2024241633A1 (en)	2023-03-30	2025-11-06	Revolution Medicines, Inc.	Compositions for inducing ras gtp hydrolysis and uses thereof
PE20260039A1 (es)	2023-04-07	2026-01-09	Revolution Medicines Inc	Inhibidores macrociclicos de ras
WO2024211663A1 (en)	2023-04-07	2024-10-10	Revolution Medicines, Inc.	Condensed macrocyclic compounds as ras inhibitors
TW202448897A (zh)	2023-04-14	2024-12-16	美商銳新醫藥公司	Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法
CN121100123A (zh)	2023-04-14	2025-12-09	锐新医药公司	Ras抑制剂的结晶形式
WO2024226579A1 (en)	2023-04-24	2024-10-31	Nested Therapeutics, Inc.	Heterocyclic derivative as mitogen-activated protein kinase (mek) inhibitor
WO2024229406A1 (en)	2023-05-04	2024-11-07	Revolution Medicines, Inc.	Combination therapy for a ras related disease or disorder
US20250049810A1 (en)	2023-08-07	2025-02-13	Revolution Medicines, Inc.	Methods of treating a ras protein-related disease or disorder
TW202515582A (zh)	2023-08-24	2025-04-16	日商大塚製藥股份有限公司	西區嘧啶(cedazuridine)之固定劑量組合
TW202530228A (zh)	2023-10-12	2025-08-01	美商銳新醫藥公司	Ｒａｓ抑制劑
US12540197B2 (en)	2023-10-13	2026-02-03	Sutro Biopharma, Inc.	Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates
TW202535891A (zh)	2023-10-20	2025-09-16	美商默沙東有限責任公司	Ｋｒａｓ蛋白之小分子抑制劑
WO2025090905A1 (en)	2023-10-26	2025-05-01	Nested Therapeutics, Inc.	Crystalline forms of 3-[[3-fluoro-2-(methylsulfamoylamino)-4-pyridyl]methyl]-7-[(3-fluoro-2-pyridyl)oxy]-4-methyl-chromen-2-one
TW202542151A (zh)	2023-12-22	2025-11-01	美商銳格醫藥有限公司	Ｓｏｓ１抑制劑及其用途
TW202547461A (zh)	2024-05-17	2025-12-16	美商銳新醫藥公司	Ｒａｓ抑制劑
WO2025250825A1 (en)	2024-05-30	2025-12-04	Sutro Biopharma, Inc.	Anti-trop2 antibodies, compositions comprising anti-trop2 antibodies and methods of making and using anti-trop2 antibodies
WO2025255438A1 (en)	2024-06-07	2025-12-11	Revolution Medicines, Inc.	Methods of treating a ras protein-related disease or disorder
WO2025259841A1 (en)	2024-06-13	2025-12-18	Nested Therapeutics, Inc.	Crystalline forms of 3-[[3-fluoro-2-(methylsulfamoylamino)-4-pyridyl]jmethyl]-7-[(3-fluoro-2-pyridyl)oxy]-4-methyl-chromen-2-one
WO2025265060A1 (en)	2024-06-21	2025-12-26	Revolution Medicines, Inc.	Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en)	2024-06-28	2026-01-02	Revolution Medicines, Inc.	Ras inhibitors
WO2026015801A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026015825A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026015790A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026035750A1 (en)	2024-08-05	2026-02-12	Pivot Therapeutics, Inc.	Inhibitors of akt and uses thereof
WO2026043823A2 (en)	2024-08-19	2026-02-26	Sutro Biopharma, Inc.	Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof
WO2026050446A1 (en)	2024-08-29	2026-03-05	Revolution Medicines, Inc.	Ras inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1996033172A1 (en) *	1995-04-20	1996-10-24	Pfizer Inc.	Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5455258A (en)	1993-01-06	1995-10-03	Ciba-Geigy Corporation	Arylsulfonamido-substituted hydroxamic acids
US5753653A (en)	1995-12-08	1998-05-19	Agouron Pharmaceuticals, Inc.	Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
CZ62799A3 (cs)	1996-08-28	1999-07-14	The Procter & Gamble Company	Heterocyklické metaloproteázové inhibitory
DE69716449T2 (de)	1996-08-28	2003-08-07	The Procter & Gamble Company, Cincinnati	Substituierte zyklische amine als metalloproteaseinhibitoren
BR9807678A (pt) *	1997-02-11	2000-02-15	Pfizer	Derivados de ácidos arilsulfonil-hidroxâmicos
JPH11199512A (ja) *	1997-10-24	1999-07-27	Pfizer Prod Inc	変形性関節症および他のｍｍｐ媒介疾患の治療のためのｍｍｐ−１３選択的阻害剤の使用

1998
- 1998-01-16 BR BR9807678-7A patent/BR9807678A/pt not_active Application Discontinuation
- 1998-01-16 SK SK1013-99A patent/SK101399A3/sk unknown
- 1998-01-16 EP EP98900124A patent/EP0960098A1/en not_active Withdrawn
- 1998-01-16 AU AU53366/98A patent/AU722784B2/en not_active Ceased
- 1998-01-16 TR TR1999/01926T patent/TR199901926T2/xx unknown
- 1998-01-16 CA CA002280151A patent/CA2280151C/en not_active Expired - Fee Related
- 1998-01-16 KR KR1019997007188A patent/KR20000070923A/ko not_active Ceased
- 1998-01-16 PL PL98334997A patent/PL334997A1/xx unknown
- 1998-01-16 EA EA199900641A patent/EA002546B1/ru not_active IP Right Cessation
- 1998-01-16 ID IDW990847A patent/ID22809A/id unknown
- 1998-01-16 IL IL13112398A patent/IL131123A0/xx not_active IP Right Cessation
- 1998-01-16 NZ NZ336836A patent/NZ336836A/en unknown
- 1998-01-16 YU YU37499A patent/YU37499A/sh unknown
- 1998-01-16 HU HU0000657A patent/HUP0000657A3/hu unknown
- 1998-01-16 WO PCT/IB1998/000064 patent/WO1998034918A1/en not_active Ceased
- 1998-01-16 CN CN98802460A patent/CN1247531A/zh active Pending
- 1998-01-16 JP JP53404098A patent/JP3710489B2/ja not_active Expired - Fee Related
- 1998-01-26 HN HN1998000020A patent/HN1998000020A/es unknown
- 1998-02-02 GT GT199800026A patent/GT199800026A/es unknown
- 1998-02-05 AP APAP/P/1998/001179A patent/AP958A/en active
- 1998-02-06 UY UY24880A patent/UY24880A1/es not_active IP Right Cessation
- 1998-02-06 PE PE1998000087A patent/PE58699A1/es not_active Application Discontinuation
- 1998-02-09 TW TW087101709A patent/TW502020B/zh not_active IP Right Cessation
- 1998-02-10 DZ DZ980026A patent/DZ2416A1/xx active
- 1998-02-10 ZA ZA9801061A patent/ZA981061B/xx unknown
- 1998-02-10 MA MA24960A patent/MA24469A1/fr unknown
- 1998-02-10 TN TNTNSN98025A patent/TNSN98025A1/fr unknown
- 1998-02-10 AR ARP980100582A patent/AR011123A1/es not_active Application Discontinuation
- 1998-02-11 CO CO98007136A patent/CO4950619A1/es unknown
- 1998-02-12 HR HR980070A patent/HRP980070B1/xx not_active IP Right Cessation
- 1998-02-15 SA SA98180856A patent/SA98180856A/ar unknown
- 1998-02-18 PA PA19988446101A patent/PA8446101A1/es unknown
1999
- 1999-07-23 IS IS5130A patent/IS5130A/is unknown
- 1999-08-05 BG BG103641A patent/BG63430B1/bg unknown
- 1999-08-06 OA OA9900174A patent/OA11142A/en unknown
- 1999-08-10 NO NO993836A patent/NO993836L/no not_active Application Discontinuation
2000
- 2000-11-08 US US09/708,328 patent/US6599890B1/en not_active Expired - Fee Related

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1996033172A1 (en) *	1995-04-20	1996-10-24	Pfizer Inc.	Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors

Also Published As

Publication number	Publication date
BG63430B1 (bg)	2002-01-31
NZ336836A (en)	2001-02-23
PL334997A1 (en)	2000-03-27
OA11142A (en)	2003-04-25
NO993836L (no)	1999-10-08
YU37499A (sh)	2002-09-19
PE58699A1 (es)	1999-06-21
EP0960098A1 (en)	1999-12-01
US6599890B1 (en)	2003-07-29
EA002546B1 (ru)	2002-06-27
AU5336698A (en)	1998-08-26
IS5130A (is)	1999-07-23
KR20000070923A (ko)	2000-11-25
GT199800026A (es)	1999-07-27
UY24880A1 (es)	2000-09-29
CA2280151C (en)	2005-12-13
AU722784B2 (en)	2000-08-10
JP3710489B2 (ja)	2005-10-26
TW502020B (en)	2002-09-11
DZ2416A1 (fr)	2003-01-04
CO4950619A1 (es)	2000-09-01
HRP980070A2 (en)	1998-12-31
SA98180856A (ar)	2005-12-03
TNSN98025A1 (fr)	2005-03-15
JP2000510162A (ja)	2000-08-08
TR199901926T2 (xx)	1999-12-21
IL131123A0 (en)	2001-01-28
BR9807678A (pt)	2000-02-15
HN1998000020A (es)	1999-01-08
HUP0000657A2 (hu)	2000-09-28
HRP980070B1 (en)	2002-10-31
ZA981061B (en)	1999-08-10
NO993836D0 (no)	1999-08-10
BG103641A (en)	2000-02-29
HUP0000657A3 (en)	2000-10-30
ID22809A (id)	1999-12-09
CN1247531A (zh)	2000-03-15
CA2280151A1 (en)	1998-08-13
MA24469A1 (fr)	1998-10-01
EA199900641A1 (ru)	2000-04-24
SK101399A3 (en)	2001-09-11
AR011123A1 (es)	2000-08-02
PA8446101A1 (es)	2000-05-24
WO1998034918A1 (en)	1998-08-13

Publication	Publication Date	Title
AP958A (en)	2001-04-17	Arylsulfonyl hydroxamic acid derivatives.
AP733A (en)	1999-02-12	Arylsulfonylamino hydroxamic acid derivatives.
RU2146671C1 (ru)	2000-03-20	Производные арилсульфонилгидроксамовой кислоты
AP826A (en)	2000-04-28	Arysulfonylamino hydroxamic acid derivatives.
IL134300A (en)	2004-07-25	Derivatives of aryloxyacrylylsulfonaminoaminoxamic acid derivatives, pharmaceutical preparations containing them and their use in the preparation of drugs for the treatment of arthritis, cancer and other diseases characterized by the activity of metalloproteinase-13 of matrix
HRP980004A2 (en)	1998-12-31	Cyclic sulfone derivatives
EP0895988B1 (en)	2002-05-22	Arylsulfonylamino hydroxamic acid derivatives
US6509337B1 (en)	2003-01-21	Arylsulfonyl Hydroxamic Acid derivatives as MMP and TNF inhibitors
MXPA99007385A (en)	2000-07-01	Arylsulfonyl hydroxamic acid derivatives
CZ9902833A3 (cs)	2000-10-11	Deriváty arylsulfonylhydroxamových kyselin, farmaceutický prostředek, způsob inhibice matričních metalloproteinas nebo produkce faktoru nekrosy nádorů a způsob léčení
KR100194258B1 (ko)	1999-06-15	아릴설포닐 하이드록삼산 유도체
MXPA99001808A (en)	1999-09-20	Arylsulfonylamino hydroxamic acid derivatives